LP-187 Abstract withdrawn
Marta Mosca(University of Pisa), Vibeke Strand(Stanford University), Brandon Becker(Bristol-Myers Squibb (United States)), Coburn Hobar(Bristol-Myers Squibb (United States)), Laurent Arnaud(Université Libre de Bruxelles), Shalabh Singhal(Integrated BioTherapeutics (United States)), Anca Askanase(Columbia University Irving Medical Center), Jiyoon Choi(Bristol-Myers Squibb (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Samantha Pomponi(Bristol-Myers Squibb (United States)), Adrian Coles(Duke University)
Cited by 2
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355